

Bronchoscopic Procedures Tested in Emphysema

BY BRUCE JANCIN
Denver Bureau

SALT LAKE CITY — Pulmonologists are developing a variety of innovative bronchoscopic procedures to achieve non-surgical lung volume reduction as treatment for advanced emphysema—and hoping to reinvent their specialty along the way.

The goal is to capitalize upon the functional and mortality benefits documented with lung volume reduction (LVR) surgery in a subset of participants in the NIH-sponsored National Emphysema Treatment Trial—but without the associated hefty perioperative mortality, major morbidity, and expense. If the bronchoscopic innovations prove successful, they could



'Maybe we'll be able to induce physiologic changes and gain time for these patients.'

DR. CELLI

transform the field of respiratory medicine, much as percutaneous angioplasty and stenting have revolutionized cardiology, speakers predicted at the annual meeting of the American College of Chest Physicians.

Planning is now underway for large, multicenter randomized trials of several novel investigational bronchoscopic LVR procedures that have successfully passed the pilot study phase of development.

Among them are insertion of one-way valves into pockets of diseased lung tissue, biologic tissue destruction with induction of scarring, and stent placement to create decompression of hyperinflated diseased lungs.

"I have this dream that you'll go into the recovery room and you'll be sweating with scrubs on and the cardiologist is going to come in and say, 'Wow, I had a tough case—I put three stents in,' and you'll say, 'Well, I had a tougher one—I put in seven valves,' or 'glued six subsegments,' or 'put in six stents.' Maybe we'll be able to induce physiologic changes and gain time for these patients," said Dr. Bartolome Celli, professor of medicine at Tufts University, Boston.

Dr. Daniel H. Sterman said that although LVR surgery didn't increase survival in the 180-patient National Emphysema Treatment Trial as a whole, it did improve survival, pulmonary functional capacity, and health status in the subset of participants with heterogenous, predominantly upper lobe emphysema and poor exercise capacity (N. Engl. J. Med. 2003;348:2059-73).

The price of surgical LVR, however, was steep: a 30-day mortality of about 5%, close to 50% major morbidity, and lengthy hospitalization. This has prompted intense research interest in developing procedures to reduce the volume of hyperinflated diseased lung without actually cutting out tissue, added Dr. Sterman, an interven-

tional pulmonologist at the University of Pennsylvania, Philadelphia. He disclosed that he has been a consultant and a member of the scientific advisory committee for Spiration Inc.

He was lead investigator in a multicenter U.S. pilot study of Spiration Inc.'s Intra-bronchial Valve (IBV), a one-way valve allowing air to escape from diseased portions of the lung, enabling the lungs to work more efficiently.

A total of 520 IBV valves were im-

planted in the upper lobes of 75 emphysema patients in the nonrandomized study, which typically involved an overnight hospital stay.

Of the 75 patients, 46 benefited, showing significantly improved general and disease-specific health status and reduced oxygen consumption with up to 1 year of follow-up. Complications in this subgroup were limited to one case of bronchospasm and one flare of chronic obstructive pulmonary disease (COPD).

Follow-up CT scans at 3 and 6 months showed significant reduction in the volume of the upper lobes of the responders, compared with their lower lobes, which increased in both volume and vascularity. This suggests the clinical benefits resulted at least in part from a redirection of ventilation and perfusion to the relatively spared lower lung segment, he explained.

Responders were younger than 75 years old, had fewer lung segments treated, and didn't have any valves placed in

Newly published data vs rosuvastatin

As an adjunct to diet when diet alone is not

What mean LDL-C reduction did and rosuvastatin did not?

- VYTORIN 10/40 mg was superior to atorvastatin 40 mg at lowering LDL-C (57% vs 48%, $P < 0.001$).¹
- VYTORIN 10/40 mg and 10/80 mg were both superior to atorvastatin 80 mg at lowering LDL-C (57% and 59% vs 53%, respectively, $P < 0.001$).¹

*Mean percent change in LDL-C from untreated baseline in a multicenter, double-blind, randomized, active-controlled, 8-arm, parallel-group study (6 weeks of active treatment) (N=1,902). Patients with hypercholesterolemia who had not met their LDL-C goal as defined by NCEP ATP III were randomized to VYTORIN 10/10, 10/20, 10/40, or 10/80 mg or atorvastatin 10, 20, 40, or 80 mg. Mean pooled baseline LDL-C values for VYTORIN and atorvastatin were 178 mg/dL and 179 mg/dL, respectively. VYTORIN 10/10 mg reduced LDL-C by 47% from baseline vs 36% with atorvastatin 10 mg ($P < 0.001$).¹

➤ The dosage should be individualized according to baseline LDL-C level, the recommended goal of therapy, and the patient's response.

VYTORIN is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia when diet alone is not enough.

Contraindications: hypersensitivity to any component of this medication; active liver disease; unexplained persistent elevations of serum transaminases; and women who are pregnant, nursing, or may become pregnant.

VYTORIN contains 2 active ingredients: ezetimibe and simvastatin.

No incremental benefit of VYTORIN on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established.

The clinical impact of comparative differences in lipid changes between products is not known.

SELECTED CAUTIONARY INFORMATION

Skeletal Muscle: Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. The risk of myopathy/rhabdomyolysis is dose related. Tell patients to promptly report muscle pain, tenderness, or weakness. Discontinue drug if myopathy is suspected or CPK levels rise markedly.

Myopathy Caused by Drug Interactions: Use of VYTORIN with itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, or large quantities of grapefruit juice (>1 quart daily) should be avoided because of the increased risk of myopathy, particularly at higher doses.

VYTORIN vs atorvastatin¹
Significantly greater LDL-C reduction*

Treatment	Mean percent change in LDL-C from untreated baseline
VYTORIN 10/20 mg	51%
atorvastatin 10 mg	36%
atorvastatin 20 mg	44%

$P < 0.001$

MERCK/Schering-Plough Pharmaceuticals

Copyright © Merck/Schering-Plough Pharmaceuticals, 2006. All rights reserved. VYTORIN is a registered trademark of MSP Singapore Company, LLC. 20607955(2)(607)-VYT

vymorin.com

the lingula. These findings will be incorporated into the upcoming large randomized trial.

Dr. Celli reported on 15 patients who have undergone a total of 21 biologic LVR treatment sessions involving instillation of a biodegradable agent.

"It has one advantage compared to the other good ideas out there: There's no foreign body left inside the individual," the physician noted.

The procedure, being developed by Aeris Therapeutics Inc., is definitely safe, said Dr. Celli, who has received research funding from the company. The only associated adverse events have been the mi-

nor sort common with flexible bronchoscopy. All patients were by protocol discharged the day after the procedure, but most could have gone home the same day, he said.

As for efficacy, early results look promising; but it will take many more patients and longer follow-up to know for sure, Dr. Celli added. The treatment concept involves identifying sick areas of lung, then instilling the biologic agent to induce atelectasis and shrink the volume so that much healthier but compressed lung tissue is allowed to expand.

A dose-response effect was apparent. The patients who have shown clinically

meaningful improvements in vital capacity and exercise capacity were the ones who received the most extensive treatment: bilateral therapy targeting up to 10% of total lung volume. Future clinical trials may target 20%-30%.

The biologic procedure's safety lends itself to repeat sessions as additional areas of lung deteriorate. One appealing but as yet untested strategy: perform biologic LVR, measure lung function, then decide if the patient needs to come back in a few weeks for further LVR to optimize results.

The patient with the best response to treatment to date is swimming for exercise

and still going strong 14 months after treatment. To physicians familiar with severe COPD, that's nothing short of miraculous, he said. But investigators haven't figured out why he's doing so well while some others who underwent extensive treatment didn't have major responses.

"We still have a long way to go," Dr. Celli emphasized.


Nonetheless, the future of nonsurgical interventions looks bright for patients with severe COPD, who traditionally have had few options other than the faint prospect of lung transplantation. Dr. Celli offered a final bit of advice to his fellow chest physicians: "Go learn bronchoscopy." ■

enough, in 2 separate head-to-head studies

VYTORIN provide that atorvastatin

50% at a usual starting dose^{1,2,3}

mean LDL-C reduction



➤ VYTORIN 10/40 mg lowered LDL-C more than rosuvastatin 20 mg (55% vs 52%, $P=0.001$).²

➤ VYTORIN 10/80 mg lowered LDL-C more than rosuvastatin 40 mg (61% vs 57%, $P<0.001$).²

[†] Data from a multicenter, randomized, double-blind, active-controlled, 6-arm, parallel-group study designed to evaluate the efficacy and safety of VYTORIN vs rosuvastatin over a 6-week period. Patients with hypercholesterolemia ($N=2,959$) were randomized to 1 of 6 treatment groups: VYTORIN 10/20, 10/40, or 10/80 mg or rosuvastatin 10, 20, or 40 mg. Mean baseline LDL-C level for both VYTORIN 10/20 mg and rosuvastatin 10 mg was 172 mg/dL.²

SELECTED CAUTIONARY INFORMATION (cont)

The concomitant use of VYTORIN and fibrates (especially gemfibrozil) should be avoided. Although not recommended, the dose of VYTORIN should not exceed 10/10 mg if used with gemfibrozil. The benefit of further alterations in lipid levels by the combined use of VYTORIN with niacin should be carefully weighed against the potential risks of myopathy. The dose of VYTORIN should not exceed 10/10 mg daily in patients receiving cyclosporine or danazol, and 10/20 mg daily in patients receiving amiodarone or verapamil.

Liver: It is recommended that liver function tests be performed before the initiation of treatment and thereafter when clinically indicated. Additional tests are recommended prior to and 3 months after titration to the 10/80-mg dose, and semiannually for the first year thereafter.

VYTORIN is not recommended in patients with moderate or severe hepatic insufficiency.

In clinical trials, the most commonly reported side effects, regardless of cause, included headache (6.8%), upper respiratory tract infection (3.9%), myalgia (3.5%), influenza (2.6%), and extremity pain (2.3%).

Please read the brief summary of Prescribing Information on the adjacent page.

References: 1. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VVA) Study. *Am Heart J*. 2005;149:464-473. 2. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. *Curr Med Res Opin*. 2006;22:2041-2053. 3. IMS HEALTH, NPA PlusSM, NRx, July 2006.

POWER MADE PRACTICAL

VYTORIN
(ezetimibe/simvastatin)
tablets